AI view21 Jan 2026 13:36
Buy" Case: Significant Undervaluation
Discount to NAV: As of late 2025, the official Net Asset Value (NAV) was 3.51p per share. However, analysts estimate the current market-based NAV is much higher, at approximately 4.81p to 5.1p per share, due to gains in its portfolio holdings.
Portfolio Wins: Recent positive momentum is driven by its subsidiary Paraytec, which launched a development program for a Parkinson's disease assay, and its stake in Imaging Biometrics (IBAI), which has seen progress in AI neuroimaging.
Strong Buy Technicals: Some technical analysts currently issue a "Strong Buy" signal based on moving averages and short-term trends.
The "Risk" Case: Volatility and Liquidity
Low Liquidity: As a small company with just 78 million shares in issue, it can be difficult to buy or sell large amounts without affecting the price.
Negative Earnings: Truetide currently has a negative price-to-earnings (PE) ratio and negative earnings per share (EPS), typical of venture capital firms waiting for a "liquidity event" (selling a company) to realize profits.
Portfolio Concentration: The stock's value is heavily tied to the success of a few clinical or technical milestones in its subsidiary companies, which carry high failure risks.